Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O75151

UPID:
PHF2_HUMAN

ALTERNATIVE NAMES:
GRC5; PHD finger protein 2

ALTERNATIVE UPACC:
O75151; Q4VXG0; Q8N3K2; Q9Y6N4

BACKGROUND:
PHD finger protein 2, known as PHF2, is integral to cellular regulation through its enzymatic activity of demethylating histones and non-histone proteins. Activation of PHF2 is contingent upon phosphorylation by PKA, which enables it to form a complex with ARID5B, targeting specific gene promoters for transcriptional activation. PHF2's role extends to coactivating HNF4A in liver function and facilitating the expression of rDNA by recruiting to trimethylated 'Lys-4' of histone H3. Its involvement in macrophage-mediated inflammatory responses through demethylation of histone H4 lysine 20 underscores its significance in immune regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of PHD finger protein 2 offers a promising avenue for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.